Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: OncoMethylome Sciences; Lucigen; Sirius Genomics; Knome

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OncoMethylome Sciences this week said that its shareholders had approved the firm's name change to MDxHealth. The Belgian firm recently announced a new strategy focused on developing molecular diagnostic tests for personalized medicine applications.


Lucigen recently announced that it has received $301,772 in Small Business Innovation Research grants to be used over the next year to support development of methods for generating complete DNA sequences from very large genomes and for the creation of DNA libraries from soil microbes for the discovery of new antibiotics.


Sirius Genomics has received an undisclosed amount of research funding from the National Research Council of Canada Industrial Research Assistance Program to discover genomic biomarkers for predicting patient response to therapeutics. The Vancouver, British Columbia-based firm is developing companion diagnostics. Its first product is a genetic predictor of response to sepsis treatment.


Knome announced this week that three researchers — from the US, Ireland, and Israel — each won free exome sequencing and analysis services from the genome analysis firm.

Abhimanyu Garg, chief of the division of nutrition and metabolic diseases at the University of Texas Southwestern Medical Center, will use the service to find the gene that causes neonatal progeroid syndrome. Eitan Friedman, head of the oncogenetics unit at the Sheba Medical Center near Tel Aviv, will use Knome's services in studies of two unrelated breast cancer patients from high-risk Ashkenazi Jewish families where no mutations in the BRCA1 and 2 genes. Judith Conroy, a postdoctoral fellow at University College Dublin, will use her Knome award to identify the genetic cause of a form of facio-audio-symphalangism.

More information on the researchers' planned studies using Knome's services can be found in this week's issue of In Sequence.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.